{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:18Z","timestamp":1793826018861,"version":"4.6.1"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.diabres.2023.110773","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T13:10:09Z","timestamp":1687612209000},"page":"110773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"special_numbering":"C","title":["Obesity and diabetes"],"prefix":"10.1016","volume":"202","author":[{"given":"Chrysoula","family":"Boutari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antea","family":"DeMarsilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2023.110773_b0005","first-page":"133","article-title":"update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"2022","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0010","first-page":"354","article-title":"Direct medical costs of obesity in the United States and the most populous states","volume":"27","author":"Cawley","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.diabres.2023.110773_b0015","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/j.metabol.2017.12.015","article-title":"Inflammation: A key player linking obesity with malignancies","volume":"81","author":"Boutari","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0020","doi-asserted-by":"crossref","unstructured":"Kahn S, Hull R, Nature KU-, 2006 undefined. Mechanisms linking obesity to insulin resistance and type 2 diabetes. NatureCom n.d.","DOI":"10.1038\/nature05482"},{"key":"10.1016\/j.diabres.2023.110773_b0025","doi-asserted-by":"crossref","unstructured":"McKeigue P, Shah B, Lancet MM-T, 1991 undefined. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Elsevier n.d.","DOI":"10.1016\/0140-6736(91)91164-P"},{"key":"10.1016\/j.diabres.2023.110773_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.metabol.2018.12.012","article-title":"The pathogenesis of obesity","volume":"92","author":"Oussaada","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0035","first-page":"13","article-title":"Effects of female obesity on conception, pregnancy and the health of offspring","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2023.110773_b0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2018.12.011","article-title":"Obesity: seize the day, fight the fat","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3803\/EnM.2018.33.1.33","article-title":"Association of adipokines with development and progression of nonalcoholic fatty liver disease","author":"Boutari","year":"2018","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.diabres.2023.110773_b0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1210\/jc.2006-1055","article-title":"Relationship between adipocyte size and adipokine expression and secretion","volume":"92","author":"Skurk","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: Emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0070","first-page":"140","article-title":"Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis","author":"Gasbarrino","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2017.10.011","article-title":"Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study","volume":"79","author":"Sahin-Efe","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0080","doi-asserted-by":"crossref","DOI":"10.3945\/ajcn.2008.26788E","article-title":"Leptin in humans: Lessons from translational research","volume":"89","author":"Bl\u00fcher","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabres.2023.110773_b0085","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jacc.2020.11.069","article-title":"Leptin in leanness and obesity: JACC state-of-the-art review","volume":"77","author":"Perakakis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2023.110773_b0090","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-130-8-199904200-00014","article-title":"The role of leptin in human obesity and disease: A review of current evidence","volume":"130","author":"Mantzoros","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2023.110773_b0095","doi-asserted-by":"crossref","unstructured":"Jung C, Kim B, Mok J, \u2026 SK-J of diabetes, 2014 undefined. Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus. Wiley Online Libr 2014;5:333\u20139. doi:10.1111\/jdi.12144.","DOI":"10.1111\/jdi.12144"},{"key":"10.1016\/j.diabres.2023.110773_b0100","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1007\/s11033-020-05732-9","article-title":"Emerging functions of adipokines in linking the development of obesity and cardiovascular diseases","volume":"47","author":"Su","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.diabres.2023.110773_b0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12291-011-0119-1","article-title":"Correlation of adiponectin and leptin with insulin resistance: A pilot study in healthy North Indian population","volume":"26","author":"Yadav","year":"2011","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.diabres.2023.110773_b0110","first-page":"14","article-title":"Obesity and leptin resistance in the regulation of the type I interferon early response and the increased risk for severe COVID-19","author":"Muskiet","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.diabres.2023.110773_b0115","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1210\/jc.2002-021808","article-title":"Serum resistin (FIZZ3) protein is increased in obese humans","volume":"88","author":"Degawa-Yamauchi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0120","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1210\/jc.2002-021604","article-title":"Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans","volume":"88","author":"Yannakoulia","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0125","first-page":"10","article-title":"Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: A systematic review and meta-analysis","author":"Su","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.diabres.2023.110773_b0130","first-page":"138","article-title":"Resistin impairs mitochondrial homeostasis via cyclase-associated protein 1-mediated fission, leading to obesity-induced metabolic diseases","author":"Yang","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2003.12.104","article-title":"Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine\u2013endothelial cell interactions","volume":"314","author":"Kawanami","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2023.110773_b0140","first-page":"22","article-title":"Production of the long pentraxin PTX3 in advanced atherosclerotic plaques","author":"Rolph","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2023.110773_b0145","doi-asserted-by":"crossref","unstructured":"Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor n.d. doi:10.1038\/s42255-021-00470-z.","DOI":"10.1038\/s42255-021-00470-z"},{"key":"10.1016\/j.diabres.2023.110773_b0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/hc0702.104279","article-title":"Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year","volume":"105","author":"Ziccardi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2023.110773_b0155","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.106.665893","article-title":"Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization","volume":"115","author":"Dahl","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2023.110773_b0160","unstructured":"Baikpour M, Baikpour M, \u2026 MH-J of M, 2017 undefined. Variations in levels of interleukins and adiponectin in normal and obese adults; a case-control study. JphysiologyCom n.d."},{"key":"10.1016\/j.diabres.2023.110773_b0165","doi-asserted-by":"crossref","unstructured":"Takumansang R, \u2026 SW-P, 2013 undefined. Interleukin-6 and insulin resistance in obese adolescents. PaediatricaindonesianaOrg 2013;53.","DOI":"10.14238\/pi53.5.2013.06"},{"key":"10.1016\/j.diabres.2023.110773_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155011","article-title":"Evaluation of metabolic syndrome, insulin secretion and insulin resistance in adolescents with overweight and obesity","volume":"128","author":"Vityala","year":"2022","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.diabres.2023.110773_b0175","first-page":"132","article-title":"Increased plasma fatty acid clearance, not fatty acid concentration, is associated with muscle insulin resistance in people with obesity","author":"Cao","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0180","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1440-1681.2011.05596.x","article-title":"Regulation of stem cell differentiation in adipose tissue by chronic inflammation","volume":"38","author":"Ye","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.diabres.2023.110773_b0185","doi-asserted-by":"crossref","unstructured":"Endocrine JY-, Disorders-Drug M& I, 2007 undefined. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. IngentaconnectCom 2007. doi:10.2174\/187153007780059423.","DOI":"10.2174\/187153007780059423"},{"key":"10.1016\/j.diabres.2023.110773_b0190","doi-asserted-by":"crossref","first-page":"E466","DOI":"10.1152\/ajpendo.00266.2012","article-title":"Inflammation during obesity is not all bad: evidence from animal and human studies","volume":"304","author":"Ye","year":"2013","journal-title":"Am J Physiol - Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0195","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI25102","article-title":"Inflammation, stress, and diabetes","volume":"115","author":"Wellen","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2023.110773_b0200","doi-asserted-by":"crossref","unstructured":"Weisberg S, McCann D, \u2026 MD-TJ of, 2003 undefined. Obesity is associated with macrophage accumulation in adipose tissue. Am Soc Clin Investig n.d.","DOI":"10.1172\/JCI200319246"},{"key":"10.1016\/j.diabres.2023.110773_b0205","doi-asserted-by":"crossref","unstructured":"Heredia F De, \u2026 SG-M-P of the, 2012 undefined. Obesity, inflammation and the immune system. CambridgeOrg 2000. doi:10.1017\/S0029665112000092.","DOI":"10.1017\/S0029665112000092"},{"key":"10.1016\/j.diabres.2023.110773_b0210","first-page":"100","article-title":"Angiogenic role of LYVE-1-positive macrophages in adipose tissue","author":"Cho","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.diabres.2023.110773_b0215","doi-asserted-by":"crossref","unstructured":"Cinti S, Mitchell G, Barbatelli G, Murano I, \u2026 EC-J of lipid, 2005 undefined. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. ASBMB n.d.","DOI":"10.1194\/jlr.M500294-JLR200"},{"key":"10.1016\/j.diabres.2023.110773_b0220","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1172\/JCI25151","article-title":"Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents","volume":"115","author":"Morino","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2023.110773_b0225","doi-asserted-by":"crossref","unstructured":"Petersen K, medicine GS-TA journal of, 2006 undefined. Etiology of insulin resistance. Elsevier n.d.","DOI":"10.1016\/j.amjmed.2006.01.009"},{"key":"10.1016\/j.diabres.2023.110773_b0230","first-page":"131","article-title":"Mitochondrial dysfunction in diabetic tubulopathy","author":"Yao","year":"2022","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.diabres.2023.110773_b0235","doi-asserted-by":"crossref","unstructured":"Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, et al. Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science (80-) 2003;300:1140\u20132. doi:10.1126\/SCIENCE.1082889\/SUPPL_FILE\/PETERSON.SOM.PDF.","DOI":"10.1126\/science.1082889"},{"key":"10.1016\/j.diabres.2023.110773_b0240","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa031314","article-title":"Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes","volume":"350","author":"Petersen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0245","doi-asserted-by":"crossref","unstructured":"Wu Z, Puigserver P, Andersson U, Cell CZ-, 1999 undefined. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Elsevier n.d.","DOI":"10.1016\/S0092-8674(00)80611-X"},{"key":"10.1016\/j.diabres.2023.110773_b0250","doi-asserted-by":"crossref","first-page":"26597","DOI":"10.1074\/jbc.M301850200","article-title":"Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells","volume":"278","author":"St-Pierre","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabres.2023.110773_b0255","first-page":"129","article-title":"Insulin: The master regulator of glucose metabolism","author":"Norton","year":"2022","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.diabres.2023.110773_b0260","unstructured":"Diabetes BC-, 2012 undefined. Banting lecture 2011: hyperinsulinemia: cause or consequence? Am Diabetes Assoc n.d."},{"key":"10.1016\/j.diabres.2023.110773_b0265","doi-asserted-by":"crossref","unstructured":"Gray S, Donald C, Jetha A, Endocrinology SC-, 2010 undefined. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic \u03b2-cell leptin signaling. AcademicOupCom n.d.","DOI":"10.1210\/en.2010-0102"},{"key":"10.1016\/j.diabres.2023.110773_b0270","doi-asserted-by":"crossref","unstructured":"Shanik MH, Xu Y, Krha JS\u02c7, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Am Diabetes Assoc 2008. doi:10.2337\/dc08-s264.","DOI":"10.2337\/dc08-s264"},{"key":"10.1016\/j.diabres.2023.110773_b0275","first-page":"23","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","author":"Del Prato","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabres.2023.110773_b0280","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.14211","article-title":"Incretins in obesity and diabetes","volume":"1461","author":"Chia","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.diabres.2023.110773_b0285","first-page":"114","article-title":"Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes","author":"Grespan","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0290","first-page":"12","article-title":"GLP-1 receptor agonists: Beyond their pancreatic effects","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2023.110773_b0295","article-title":"Novel non-invasive approaches to the treatment of obesity: From pharmacotherapy to gene therapy","author":"Angelidi","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.diabres.2023.110773_b0300","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110773_b0305","doi-asserted-by":"crossref","first-page":"941","DOI":"10.33549\/physiolres.932151","article-title":"GIP-dependent expression of hypothalamic genes","volume":"60","author":"Ambati","year":"2011","journal-title":"Physiol Res"},{"key":"10.1016\/j.diabres.2023.110773_b0310","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9150(00)00514-1","article-title":"Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men","volume":"154","author":"Lakka","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2023.110773_b0315","first-page":"120","article-title":"The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis","author":"Liu","year":"2021","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.diabres.2023.110773_b0320","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/aje\/kwf114","article-title":"Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study","volume":"156","author":"Stevens","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diabres.2023.110773_b0325","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.0.1500195","article-title":"Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans","volume":"150","author":"Pontiroli","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diabres.2023.110773_b0330","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110773_b0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0002-9149(02)02749-2","article-title":"Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity","volume":"90","author":"Kwiterovich","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabres.2023.110773_b0340","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.ATV.20.3.830","article-title":"LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study","volume":"20","author":"Howard","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2023.110773_b0345","first-page":"1962","article-title":"In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus","volume":"86","author":"Fr\u00e9nais","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0350","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-1018","article-title":"Free fatty acids and atherosclerosis\u2014Guilty or innocent?","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0355","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1210\/jc.2006-0195","article-title":"Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease","volume":"91","author":"Pilz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0360","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jama.280.21.1843","article-title":"Abdominal adiposity and coronary heart disease in women","volume":"280","author":"Rexrode","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2023.110773_b0365","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-144-7-200604040-00011","article-title":"Adiposity of the heart, revisited","volume":"144","author":"McGavock","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2023.110773_b0370","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mrm.10372","article-title":"Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging","volume":"49","author":"Szczepaniak","year":"2003","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.diabres.2023.110773_b0375","doi-asserted-by":"crossref","unstructured":"Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertens (Dallas, Tex 1979) 2004;44:271\u20136. doi:10.1161\/01.HYP.0000140058.28994.EC.","DOI":"10.1161\/01.HYP.0000140058.28994.ec"},{"key":"10.1016\/j.diabres.2023.110773_b0380","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1172\/JCI13143","article-title":"Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity","volume":"108","author":"Konstantinides","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2023.110773_b0385","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1161\/01.CIR.0000033219.24717.52","article-title":"Influence of Leptin on Arterial Distensibility","volume":"106","author":"Singhal","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2023.110773_b0390","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.ATV.0000077401.36885.BB","article-title":"Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation","volume":"23","author":"Alessi","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2023.110773_b0395","doi-asserted-by":"crossref","unstructured":"haematology CE-B journal of, 2005 undefined. The interactions between inflammation and coagulation. Wiley Online Libr 2005;131:417\u201330. doi:10.1111\/j.1365-2141.2005.05753.x.","DOI":"10.1111\/j.1365-2141.2005.05753.x"},{"key":"10.1016\/j.diabres.2023.110773_b0400","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2023.110773_b0405","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0410","first-page":"122","article-title":"Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward","author":"Boutari","year":"2021","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.diabres.2023.110773_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154968","article-title":"Factors associated with hepatic steatosis in adult Greek subjects with type 2 diabetes mellitus","volume":"128","author":"Meritsi","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0420","first-page":"123","article-title":"Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea","author":"Chung","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0425","doi-asserted-by":"crossref","unstructured":"Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis 2015. doi:10.3390\/nu7115475.","DOI":"10.3390\/nu7115475"},{"key":"10.1016\/j.diabres.2023.110773_b0430","unstructured":"endocrinology HY-J-T lancet D&, 2014 undefined. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Elsevier n.d."},{"key":"10.1016\/j.diabres.2023.110773_b0435","doi-asserted-by":"crossref","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013 106 2013;10:330\u201344. doi:10.1038\/nrgastro.2013.41.","DOI":"10.1038\/nrgastro.2013.41"},{"key":"10.1016\/j.diabres.2023.110773_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00017.2012","article-title":"Hypoxia and adipose tissue function and dysfunction in obesity","volume":"93","author":"Trayhurn","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.diabres.2023.110773_b0445","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2023.110773_b0450","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: Mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110773_b0455","first-page":"97","article-title":"Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study","author":"Turer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0460","doi-asserted-by":"crossref","unstructured":"Machado M V, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease CONCISE REVIEW 2012;11:440\u20139.","DOI":"10.1016\/S1665-2681(19)31457-7"},{"key":"10.1016\/j.diabres.2023.110773_b0465","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2023.110773_b0470","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.2337\/dc23-S014","article-title":"14. Children and adolescents: Standards of care in diabetes\u20142023","volume":"46","author":"Elsayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"Suppl 3","key":"10.1016\/j.diabres.2023.110773_b0475","first-page":"1","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"10.1016\/j.diabres.2023.110773_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2021.111442","article-title":"Bioelectrical impedance analysis as an alternative to dual-energy x-ray absorptiometry in the assessment of fat mass and appendicular lean mass in patients with obesity","volume":"93","author":"Ballesteros-Pomar","year":"2022","journal-title":"Nutrition"},{"key":"10.1016\/j.diabres.2023.110773_b0485","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.clnu.2018.04.018","article-title":"Sarcopenic obesity: Time to meet the challenge","volume":"37","author":"Barazzoni","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.diabres.2023.110773_b0490","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/epirev\/mxm008","article-title":"Comparison of body mass index, waist circumference, and waist\/hip ratio in predicting incident diabetes: a meta-analysis","volume":"29","author":"Vazquez","year":"2007","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.diabres.2023.110773_b0495","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc14-2391","article-title":"BMI cut points to identify at-risk asian americans for type 2 diabetes screening","volume":"38","author":"Hsu","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2019.tb00055.x","article-title":"Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus","volume":"9","author":"Burhans","year":"2018","journal-title":"Compr Physiol"},{"key":"10.1016\/j.diabres.2023.110773_b0505","first-page":"7","article-title":"Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease","author":"Chait","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabres.2023.110773_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2023.03.272","article-title":"American Association of Clinical Endocrinology Consensus Statement: Addressing stigma and bias in the diagnosis and management of patients with obesity\/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severi","author":"Nadolsky","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2023.110773_b0515","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc23-S008","article-title":"8. obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0520","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1467-789X.2011.00952.x","article-title":"Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis","volume":"13","author":"Ashwell","year":"2012","journal-title":"Obes Rev An Off J Int Assoc Study Obes"},{"key":"10.1016\/j.diabres.2023.110773_b0525","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MED.0000000000000360","article-title":"Current body composition measurement techniques","volume":"24","author":"Lemos","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.diabres.2023.110773_b0530","doi-asserted-by":"crossref","unstructured":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913\u201321. doi:10.1016\/S2213-8587(16)30162-0.","DOI":"10.1016\/S2213-8587(16)30162-0"},{"key":"10.1016\/j.diabres.2023.110773_b0535","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2023.110773_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.155080","article-title":"Epidemiological study on short and long-term weight loss with improvement of metabolic control in obese diabetic patients with a standardized multidisciplinary weight loss program (DIAMEX Study)","volume":"128","author":"Nach\u00f3n","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0545","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/ds17-0016","article-title":"The look AHEAD trial: Translating lessons learned into clinical practice and further study","volume":"30","author":"Salvia","year":"2017","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.diabres.2023.110773_b0550","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1001\/jama.2012.67929","article-title":"Association of an intensive lifestyle intervention with remission of type 2 diabetes","volume":"308","author":"Gregg","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2023.110773_b0555","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2023.110773_b0560","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2023.110773_b0565","doi-asserted-by":"crossref","first-page":"e029966","DOI":"10.1136\/bmjopen-2019-029966","article-title":"Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials","volume":"9","author":"Singh","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabres.2023.110773_b0570","unstructured":"Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes | NEJM n.d. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1212914?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0www.ncbi.nlm.nih.gov."},{"key":"10.1016\/j.diabres.2023.110773_b0575","doi-asserted-by":"crossref","unstructured":"Group LAR, Wadden TA, West DS, Delahanty L, Jakicic J, Rejeski J, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) 2006;14:737\u201352. doi:10.1038\/oby.2006.84.","DOI":"10.1038\/oby.2006.84"},{"key":"10.1016\/j.diabres.2023.110773_b0580","doi-asserted-by":"crossref","unstructured":"Group LAR. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014;22:5\u201313. doi:10.1002\/oby.20662.","DOI":"10.1002\/oby.20662"},{"key":"10.1016\/j.diabres.2023.110773_b0585","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/oby.21172","article-title":"Improving diabetes outcomes through lifestyle change \u2013 A randomized controlled trial","volume":"23","author":"Delahanty","year":"2015","journal-title":"Obesity"},{"key":"10.1016\/j.diabres.2023.110773_b0590","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/oby.23508","article-title":"Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trial","volume":"30","author":"Wexler","year":"2022","journal-title":"Obesity"},{"key":"10.1016\/j.diabres.2023.110773_b0595","doi-asserted-by":"crossref","unstructured":"Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study. Obesity (Silver Spring) 2014;22:5\u201313. doi:10.1002\/oby.20662.","DOI":"10.1002\/oby.20662"},{"key":"10.1016\/j.diabres.2023.110773_b0600","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1467-789X.2010.00740.x","article-title":"Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review","volume":"11","author":"Barte","year":"2010","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabres.2023.110773_b0605","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.diabres.2023.110773_b0610","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2023.110773_b0615","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dci19-0014","article-title":"Nutrition therapy for adults with diabetes or prediabetes: A consensus report","volume":"42","author":"Evert","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0620","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.diabres.2023.110773_b0625","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0630","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2023.110773_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: An update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0645","first-page":"118","article-title":"Diabetes mellitus: 100 years since the discovery of insulin","author":"Polyzos","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0650","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.diabres.2023.110773_b0655","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2023.110773_b0660","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabres.2023.110773_b0665","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0670","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: Available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0675","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0680","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1463-1326.2002.00237.x","article-title":"The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial","volume":"4","author":"Hanefeld","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0685","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0690","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0695","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2023.110773_b0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss","volume":"84","author":"Billes","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabres.2023.110773_b0710","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabres.2023.110773_b0715","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients","author":"Hollander","year":"2013","journal-title":"Am Diabetes Assoc"},{"key":"10.1016\/j.diabres.2023.110773_b0720","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.diabres.2023.110773_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155375","article-title":"Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies","volume":"140","author":"Watkins","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2023.110773_b0730","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0735","doi-asserted-by":"crossref","unstructured":"Davies MJ, Bergenstal R, Bode B. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial 2015.","DOI":"10.1001\/jama.2015.9676"},{"key":"10.1016\/j.diabres.2023.110773_b0740","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.diabres.2023.110773_b0745","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","article-title":"The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1\u20135 studies","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0750","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2023.110773_b0755","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0760","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2023.110773_b0765","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2023.110773_b0770","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0775","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2023.110773_b0780","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2265.2008.03451.x","article-title":"Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes","volume":"71","author":"Daousi","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.diabres.2023.110773_b0785","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2337\/dbi21-0001","article-title":"The role of GIP receptor in the CNS for the pathogenesis of obesity","volume":"70","author":"Fukuda","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2023.110773_b0790","unstructured":"Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities | Eli Lilly and Company n.d. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-receives-us-fda-fast-track-designation-tirzepatide."},{"key":"10.1016\/j.diabres.2023.110773_b0795","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0800","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0805","unstructured":"Lilly\u2019s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 | Eli Lilly and Company n.d. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or."},{"key":"10.1016\/j.diabres.2023.110773_b0810","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2023.110773_b0815","doi-asserted-by":"crossref","unstructured":"Hope DCD, Vincent ML, Tan TMM. Striking the Balance: GLP-1\/Glucagon Co-Agonism as a Treatment Strategy for Obesity. Front Endocrinol (Lausanne) 2021;12.","DOI":"10.3389\/fendo.2021.735019"},{"key":"10.1016\/j.diabres.2023.110773_b0820","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12902-022-01031-5","article-title":"Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"22","author":"Ali","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.diabres.2023.110773_b0825","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: A 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2023.110773_b0830","article-title":"AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist","author":"Healthcare","year":"2023","journal-title":"Pharm Technol"},{"key":"10.1016\/j.diabres.2023.110773_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0840","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dom.14948","article-title":"Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor\/glucagon-like peptide-1 receptor agonist BI 456906","volume":"25","author":"Jungnik","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2023.110773_b0845","unstructured":"Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight 2023. https:\/\/www.businesswire.com\/news\/home\/20230510005447\/en\/Boehringer-Ingelheim-and-Zealand-Pharma-announce-phase-II-trial-showed-14.9-weight-loss-in-people-living-with-obesity-or-overweight."},{"key":"10.1016\/j.diabres.2023.110773_b0850","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A randomized, double-blind, placebo-controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.diabres.2023.110773_b0855","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.diabres.2023.110773_b0860","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11695-016-2457-9","article-title":"Metabolic surgery in the treatment algorithm for type 2 diabetes: a Joint Statement by International Diabetes Organizations","volume":"27","author":"Rubino","year":"2017","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabres.2023.110773_b0865","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications","volume":"311","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2023.110773_b0870","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/193229681200600528","article-title":"Treatment of diabetes prior to and after bariatric surgery","volume":"6","author":"Thorell","year":"2012","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.diabres.2023.110773_b0875","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabres.2023.110773_b0880","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2023.110773_b0885","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00268-021-06394-9","article-title":"Guidelines for perioperative care in bariatric surgery: Enhanced recovery after surgery (ERAS) society recommendations: A 2021 update","volume":"46","author":"Stenberg","year":"2022","journal-title":"World J Surg"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723005363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822723005363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:28:07Z","timestamp":1759174087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822723005363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":177,"alternative-id":["S0168822723005363"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110773","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity and diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2023.110773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110773"}}